IP Library Granted Patent US 10,525,028
Granted Patent B2
US 10,525,028 · App. 14/928,369 · Granted Jan 7, 2020

Composition for external use on skin for inflammatory diseases

Inventors: Jiro Takeo (Tokyo, JP); Hiroyuki Kawahara (Tokyo, JP)
Assignee: NIPPON SUISAN KAISHA, LTD.
A61K31/202A61K9/0014A61K31/232A61K31/683A61K31/685A61K31/7032A61K47/06A61P17/00A61P17/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,525,028
App. No.
14/928,369
Granted
Jan 7, 2020
Kind
B2
Abstract

[Problem] To provide a composition for external skin use that has anti-inflammatory and antiallergic activity, and is very safe. [Solution] A composition for external skin use for inflammatory diseases contains dihomo-gamma-linolenic acid (DGLA) as the active ingredient thereof. It is preferable for the DGLA to be present as a glyceride, a phospholipid, or an alkyl ester. The amount of DGLA contained in the composition for external use is 0.1-50 wt %.

Claims (11)

1. A method of suppressing an itch of inflammatory disease comprising administering topically, to the skin of a patient in need thereof, an effective amount of dihomo-γ-linolenic acid (DGLA),

wherein the DGLA is provided in the form of an oil derived from a culture of micro-organisms of genus Mortierella , and

wherein the DGLA is applied continuously for at least 14 consecutive days to an area affected by the inflammatory disease.

2. The method according to claim 1 , wherein the dihomo-γ-linolenic acid (DGLA) is in the form of any one of a glyceride, a phospholipid, a glycolipid, an alkyl ester, a salt, or a free fatty acid.

3. The method according to claim 2 , wherein the glyceride is a triglyceride, a diglyceride, or a monoglyceride.

4. The method according to claim 2 , wherein the alkyl ester is an ester with a lower C 1-4 alcohol.

5. The method according to claim 2 , wherein the phospholipid is diacylglycerophospholipid or lysoacylglycerophospholipid.

6. The method according to claim 1 , wherein the dihomo-γ-linolenic acid (DGLA) is administered in a composition containing 0.01 to 50 wt % of the dihomo-γ-linolenic acid (DGLA).

7. The method according to claim 1 , wherein the inflammatory disease is an inflammatory skin disease.

8. The method according to claim 7 , wherein the inflammatory disease is atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, psoriasis, rheumatism, or lupus.

9. The method according to claim 1 , wherein the DGLA is administered in the form of an ointment comprising DGLA containing oil and zinc oxide.

Priority Claims (1)
JP 2011-107512 · May 12, 2011 · national
Continuity (2)
Division 14117330
Related Publication 20160051504A1 · Feb 25, 2016